Samyang Holdings Presents Clinical Cases of 'Lafullen® and Croquis®' at KOAT Academic Conference

October 30, 2023 11:00 AM AEDT | By Cision

Google News:

Samyang Holdings Presents Clinical Cases of 'Lafullen® and Croquis®' at KOAT Academic Conference — Image source: Kalkine Media

Recent News

Hydrogen Power Meets Carbon Credits: NoviqTech and HYDI Set Sights on...

North Bay’s Bishop Operations Mark Steady Progress as Gold Prices Stab...

Battery Strategist Joins Firebird Metals (ASX:FRB) to Drive Western Gr...

Animoca’s Moca Chain Eyes 2025 Rollout to Reshape Digital Identity wit...

Presentation of "Lafullen^®" and "Croquis^®" Procedures and Clinical Cases... Confirming Product Excellence and Safety
Biodegradable Polymer Filler "Lafullen^®" Maintains Natural Volume for 2 Years
"Croquis®" Lifting Threads with Samyang' expertise in Global Biodegradable Suture Threads

SEOUL, South Korea, Oct. 30, 2023 /PRNewswire/ -- On the 22nd of October, Samyang Holdings Biopharm Group (Represented by Young-joon Lee) presented clinical cases demonstrating the efficacy and safety of the biodegradable polymer filler "Lafullen^®" and lifting threads "Croquis^®" at the Korean Academy of Obesity & Aesthetic Treatment (KOAT) Annual Conference held at COEX in Gangnam, Seoul.

KOAT is the largest Korean medical aesthetics academy composed of 12,000 members, established in 2022. Samyang presented clinical cases for effective and safe procedures with Lafullen^® and Croquis^® at this academic conference.

The President of the KOAT, Dr. Seung-guk Hwang, the President of the Korean Filler Education & Research Academy, Dr. Jae-wook Lew, and the Operating Director of the Korean Filler Education & Research Academy, Dr. Ho-Won Lee, each took the stage to share the results they confirmed through procedures. President Hwang stated, "As the trends in the medical aesthetics market are shifting towards pursuing natural beauty, Lafullen^® exhibits a natural volume resulting in high satisfaction among patients."

Lafullen^®, a dermal filler primarily composed of biodegradable polymer for medical use known as Polycaprolactone (PCL), with a duration of over 2 years. It provides a natural volume with less irritation, benefiting from Samyang's patented technology. Samyang has been expanding into global dermal market with obtaining Lafullen^® approval in Indonesia and signing a partnership agreement with Chinese medical devices and aesthetics specialist company for the export of Lafullen^®.

Croquis^® is a lifting thread primarily composed of Polydioxanone (PDO), a biocompatible polymer material. It embodies Samyang ' expertise in the field of biodegradable suture threads, received CE MDD (Medical Devices Directive) certification in 2019. It signed sales contracts in 18 countries worldwide, including the EU, Japan, and Latin America. It is also in the process of obtaining regulatory marketing approval in the US.

Samyang Holdings CEO Young-joon Lee stated, "Lafullen^® and Croquis^® are medical device products developed by Samyang through our in-house research and development, based on our extensive research in polymer materials," and further mentioned, "We will continue accumulating clinical cases and research results from both domestic and international medical fields, aiming to substantiate their excellence and safety on an evidence-based foundation."

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.